Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers

References

• Asanuma, K., et al., 2020. Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas. Scientific reports, 10 (1), 9077.
   PubMed Web of Science ®Google Scholar
• Akutsu, Y., et al., 2018. The concentration of programmed cell deathligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Esophagus, 15 (2), 103–108.
   PubMed Web of Science ®Google Scholar
• Aghajani, M.J., et al., 2019. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. Endocrine connections, 8 (7), 1040–1051.
   PubMed Web of Science ®Google Scholar
• Binnewies, M., et al., 2018. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature medicine, 24 (5), 541–550.
   PubMed Web of Science ®Google Scholar
• Bi, X.W., et al., 2016. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. Journal of hematology & oncology, 9, 109.
   PubMed Web of Science ®Google Scholar
• Buderath, P., et al., 2019. Soluble programmed death receptor ligands sPD-L1 and sPD-L2 as liquid biopsy markers for prognosis and platinum response in epithelial ovarian cancer. Frontiers in oncology, 9, 1015.
   PubMed Web of Science ®Google Scholar
• Bian, B., et al., 2019. Prognostic significance of circulating PD-1, PD-L1, panBTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology, 8 (4), e1561120.
   PubMed Web of Science ®Google Scholar
• Cochran, W., 1954. The combination of estimates from different experiments. Biometrics, 10 (1), 101–129.
   Web of Science ®Google Scholar
• Davis, A.A., and Patel, V.G., 2019. The role of PD-L1 expression as a predictive biomarker: An analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. Journal for immunotherapy of cancer., 7, 278.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack, I., and Shaw, A.T., 2018. Tumour heterogeneity and resistance to cancer therapies. Nature reviews. Clinical oncology, 15 (2), 81–94.
   PubMed Web of Science ®Google Scholar
• Ding, Y., et al., 2017. The prognostic significance of soluble programmed death ligand 1 expression in cancers: a systematic review and meta-analysis. Scandinavian journal of immunology, 86 (5), 361–367.
   PubMed Web of Science ®Google Scholar
• Doroshow, D.B., et al., 2021. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature reviews. Clinical oncology, 18 (6), 345–362.
   PubMed Web of Science ®Google Scholar
• Duval, S., and Tweedie, R., 2000. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. Journal of the American statistical association, 95, 89–98.
   Web of Science ®Google Scholar
• Derigs, M., et al., 2022. Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome. Immunologic research, 70 (5), 698–707.
   PubMed Web of Science ®Google Scholar
• Fan, Y.B., et al., 2019. Exosomal PD-L1 Retains immunosuppressive activity and is associated with gastric cancer prognosis. Annals of surgical oncology, 26 (11), 3745–3755.
   PubMed Web of Science ®Google Scholar
• Finkelmeier, F., et al., 2016. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. European journal of cancer (Oxford, England: 1990), 59, 152–159.
   PubMed Web of Science ®Google Scholar
• Fukuda, T., et al., 2016. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer medicine, 5 (8), 1810–1820.
   PubMed Web of Science ®Google Scholar
• Fei, Y., et al., 2020. Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. Journal of cancer, 11 (23), 7001–7008.
   PubMed Web of Science ®Google Scholar
• Fu, R., et al., 2021. Prognostic significance of serum PD-L1 level in patients with locally advanced or metastatic esophageal squamous cell carcinoma treated with combination cytotoxic chemotherapy. Cancer management and research, 13, 4935–4946.
   PubMed Web of Science ®Google Scholar
• Gong, B., et al., 2019. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer. The journal of experimental medicine, 216 (4), 982–1000.
   PubMed Web of Science ®Google Scholar
• Huang, P., et al., 2020. The prognostic value of circulating soluble programmed death ligand-1 in cancers: a meta-analysis. Frontiers in oncology, 10, 626932.
   PubMed Web of Science ®Google Scholar
• Higgins, J.P.T., and Thompson, S.G., 2002. Quantifying heterogeneity in a meta-analysis. Statistics in medicine, 21 (11), 1539–1558.
   PubMed Web of Science ®Google Scholar
• Han, X., et al., 2019. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. Journal of cancer research and clinical oncology, 145 (2), 303–312.
   PubMed Web of Science ®Google Scholar
• Ha, H., et al., 2016. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget, 7 (47), 76604–76612.
   PubMedGoogle Scholar
• Han, B., et al., 2021. The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte. Cancer immunology, immunotherapy: CII, 70 (10), 2893–2909.
   PubMed Web of Science ®Google Scholar
• Ito, M., et al., 2020. High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer. Cancer medicine, 9 (4), 1321–1327.
   PubMed Web of Science ®Google Scholar
• Ito, M., et al., 2018. Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer? Annals of gastroenterological surgery, 2 (4), 313–318.
   PubMed Web of Science ®Google Scholar
• Kruger, S., et al., 2017. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology, 6 (5), e1310358.
   PubMed Web of Science ®Google Scholar
• Korman, A.J., Garrett-Thomson, S.C., and Lonberg, N., 2022. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature reviews. Drug discovery, 21 (7), 509–528.
   PubMed Web of Science ®Google Scholar
• Krafft, U., et al., 2021. High serum PD-L1 levels are associated with poor survival in urothelial cancer patients treated with chemotherapy and immune checkpoint inhibitor therapy. Cancers (Basel), 13, 2548.
   PubMed Web of Science ®Google Scholar
• Kim, H.J., et al., 2018. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiotherapy and oncology, 129 (1), 130–135.
   PubMed Web of Science ®Google Scholar
• Li, J.W., et al., 2020. Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type. American journal of cancer research, 10, 4498–4512.
   PubMed Web of Science ®Google Scholar
• Li, X., Zheng, Y., and Yue, F., 2021. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in various cancers: a meta-analysis. Targeted oncology, 16 (1), 13–26.
   PubMed Web of Science ®Google Scholar
• Morad, G., et al., 2021. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell, 184 (21), 5309–5337.
   PubMed Web of Science ®Google Scholar
• Murakami, S., et al., 2020. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Thoracic cancer, 11 (12), 3585–3595.
   PubMed Web of Science ®Google Scholar
• Mocan, T., et al., 2021. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. International immunopharmacology, 94, 107467.
   PubMed Web of Science ®Google Scholar
• Meyo, M.T., et al., 2020. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers (Basel), 12, 473.
   PubMed Web of Science ®Google Scholar
• Ma, X.L., et al., 2020. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. Clinica chimica acta; international journal of clinical chemistry, 511, 67–74.
   PubMed Web of Science ®Google Scholar
• Nukui, A., et al., 2017. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy. BMC cancer, 17 (1), 372.
   PubMed Web of Science ®Google Scholar
• Oh, S.Y., et al., 2021. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Scientific reports, 11 (1), 19712.
   PubMed Web of Science ®Google Scholar
• Okuma, Y., et al., 2017. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung cancer (Amsterdam, Netherlands), 104, 1–6.
   PubMed Web of Science ®Google Scholar
• Okuma, Y., et al., 2018. Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non-small-cell lung cancer. Clinical lung cancer, 19 (5), 410–417.e1.
   PubMed Web of Science ®Google Scholar
• Park, H., et al., 2019. prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Scientific reports, 9 (1), 11131.
   PubMedGoogle Scholar
• Rossille, D., et al., 2014. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma. Leukemia, 28 (12), 2367–2375.
   PubMed Web of Science ®Google Scholar
• Roderburg, C., et al., 2021. Levels of circulating PD-L1 are decreased in patients with resectable cholangiocarcinoma. International journal of molecular sciences., 22, 6569.
   PubMed Web of Science ®Google Scholar
• Shi, L., et al., 2013. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. Journal of hematology & oncology, 6 (1), 74.
   PubMedGoogle Scholar
• Sidaway, P., 2019. PD-L1 positivity predicts response. Nature reviews. Clinical oncology, 16 (6), 337.
   Web of Science ®Google Scholar
• Stang, A., 2010. Critical evaluation of the Newcastle–Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology, 25 (9), 603–605.
   PubMed Web of Science ®Google Scholar
• Sun, J., et al., 2020. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer. Translational cancer research, 9 (4), 2434–2448.
   PubMed Web of Science ®Google Scholar
• Shigemori, T., et al., 2019. Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: direct comparison of the clinical burden between tissue and serum PD-L1 expression. Annals of surgical oncology, 26 (3), 876–883.
   PubMed Web of Science ®Google Scholar
• Shen, H., et al., 2019. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. Hematology, 24 (1), 392–398.
   PubMed Web of Science ®Google Scholar
• Tierney, J.F., et al., 2007. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16.
   PubMed Web of Science ®Google Scholar
• Takahashi, N., et al., 2016. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first‑line treatment of metastatic or recurrent gastric cancer. Journal of cancer research and clinical oncology, 142 (8), 1727–1738.
   PubMed Web of Science ®Google Scholar
• Vanga, R.R., et al., 2018. Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency-systematic review and meta-analysis. Clinical gastroenterology and hepatology, 16 (8), 1220–1228.e4.
   PubMed Web of Science ®Google Scholar
• Wei, W., et al., 2018. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: a meta-analysis. Medicine, 97 (3), e9617.
   PubMed Web of Science ®Google Scholar
• Wang, L., et al., 2015. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget, 6 (38), 41228–41236.
   PubMedGoogle Scholar
• Wang, H., et al., 2016. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. Oncotarget, 7 (22), 33035–33045.
   PubMedGoogle Scholar
• Zheng, Z., et al., 2014. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chinese journal of cancer research, 26, 104–111.
   PubMed Web of Science ®Google Scholar
• Zhang, J., et al., 2015. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thoracic cancer, 6 (4), 534–538.
   PubMed Web of Science ®Google Scholar
• Zhao, J., et al., 2017. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Medicine, 96 (7), e6102.
   PubMed Web of Science ®Google Scholar